Advertisement

PharmacoEconomics & Outcomes News

, Volume 844, Issue 1, pp 12–12 | Cite as

Ceritinib cost effective for ALK-positive advanced NSCLC in China

Clinical study
  • 1 Downloads

Reference

  1. Li H, et al. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer. Clinical Drug Investigation : 9 Dec 2019. Available from: URL: https://doi.org/10.1007/s40261-019-00880-8

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations